Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol SAKK 18/ 25 Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors: A Multicenter, Single-arm, Open-label Phase II Trial (ORIGIN2)

NCT07158489 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07158489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07158489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol SAKK 18/ 25 Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors: A Multicenter, Single-arm, Open-label Phase II Trial (ORIGIN2)
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
August 21, 2026
Completion date
July 31, 2029
Enrollment
47 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, nsclc (advanced non-small cell lung cancer)